Press Releases

BlueSphere Bio to Present a Corporate Overview at the 2022 BIO International Convention

PITTSBURGH, PA, June 13, 2022 — BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for patients with hematologic malignancies and solid tumors, today announced that David Apelian, M.D., Ph.D., MBA, Chief Executive Officer of BlueSphere Bio, will provide a corporate overview at the 2022 …

BlueSphere Bio to Present a Corporate Overview at the 2022 BIO International Convention Read More »

BlueSphere Bio Data to be Presented at the 2022 Joint ASTCT + EBMT Basic and Translational Scientific Retreat

PITTSBURGH, PA, May 25, 2022 — BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for patients with hematologic malignancies and solid tumors, today announced that Sawa Ito, M.D., Ph.D., was selected to provide an oral presentation during the 2022 Joint ASTCT + EBMT Basic …

BlueSphere Bio Data to be Presented at the 2022 Joint ASTCT + EBMT Basic and Translational Scientific Retreat Read More »

BlueSphere Bio Appoints Robert Keefe, Ph.D. as Chief Development Office

Dr. Keefe to lead the product development and manufacturing of BlueSphere Bio’s first clinical candidate, a TCR T-cell therapy directed against the miHA HA-1. PITTSBURGH, PA, April 26, 2022 — BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for patients with hematologic malignancies and …

BlueSphere Bio Appoints Robert Keefe, Ph.D. as Chief Development Office Read More »

BlueSphere Bio Presents New Data Supporting the Potential of its TCXpress™ Platform at the 2022 AACR Meeting

TCXpress™ identified a diverse set of novel T-cell receptors (TCRs) with in vitro reactivity against the minor histocompatibility antigen HA-1, from a single donor Data support the broad potential of TCXpress™ to rapidly and efficiently identify TCRs with activity against a selected target PITTSBURGH, PA, April 8, 2022 — BlueSphere Bio, a T-cell receptor (TCR) …

BlueSphere Bio Presents New Data Supporting the Potential of its TCXpress™ Platform at the 2022 AACR Meeting Read More »

BlueSphere Bio Data to be Presented at the 2022 American Association for Cancer Research Annual Meeting

PITTSBURGH, PA, March 15, 2022 — BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a revolutionary TCR discovery platform and novel therapeutic candidates for patients with hematologic malignancies and solid tumors, today announced that Sawa Ito, M.D., Ph.D., hematologist/oncologist at UPMC Hillman Cancer Center and Assistant Professor, Division of Hematology-Oncology and of Immunology …

BlueSphere Bio Data to be Presented at the 2022 American Association for Cancer Research Annual Meeting Read More »

BlueSphere Bio to Present at the BIO CEO & Investor Conference

PITTSBURGH, PA, February 8, 2022 — BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a revolutionary TCR discovery platform and novel therapeutic candidates for patients with hematologic malignancies and solid tumors, today announced that David Apelian, M.D., Ph.D., MBA, chief executive officer of BlueSphere Bio, will present an in-person company overview at the …

BlueSphere Bio to Present at the BIO CEO & Investor Conference Read More »

BlueSphere Bio appoints industry veteran Jonathan Peacock as Chairman of the Board

Today BlueSphere Bio announces the appointment of Jonathan Peacock as Chairman of the Board of Directors in its pursuit to build an industry leading Board and executive team to develop their groundbreaking immune oncology T cell receptor (TCR) T-cell discovery platform and clinical programs. Mr. Peacock brings a wealth of experience from the biotech and …

BlueSphere Bio appoints industry veteran Jonathan Peacock as Chairman of the Board Read More »

BlueSphere Bio Names Dr. Alan Korman to Board of Directors

Immuno-oncology startup BlueSphere Bio, a company developing its novel T cell receptor search and capture platform, TCXpress, to create rapid personalized T cell therapies for cancer and blood and marrow transplantation, has named immunotherapy pioneer Alan Korman, Ph.D., to its board of directors. Korman brings more than three decades of immunotherapy and biotechnology experience to …

BlueSphere Bio Names Dr. Alan Korman to Board of Directors Read More »

BlueSphere Bio Appoints Drug Development Leader Dr. Michael Geffner as Chief Medical Officer

BlueSphere Bio, which was established by UPMC Enterprises, uses its novel TCXpress platform to obtain and characterize T cell receptors, the key component for any T cell immunotherapy. This technology, developed at the University of Pittsburgh, is an efficient, cost-effective alternative to conventional methods of using a person’s own T cells to create individualized treatments. …

BlueSphere Bio Appoints Drug Development Leader Dr. Michael Geffner as Chief Medical Officer Read More »

BlueSphere Bio Names Immune Oncology Pioneers to Scientific Advisory Board

BlueSphere Bio, an immunotherapy startup focused on creating personalized T cell therapies for cancer, today announced the members of its newly formed scientific advisory board. Composed of internationally renowned scientists with deep expertise that spans basic T cell immunology to cutting edge adoptive T cell immunotherapies, the board will provide vital guidance for BlueSphere Bio …

BlueSphere Bio Names Immune Oncology Pioneers to Scientific Advisory Board Read More »